Latest News

In recent months, Wave Life Sciences has drawn increased attention for its PRISM RNA medicines platform and its work with partners including GlaxoSmithKline, Takeda Pharmaceutical, and Asuragen to advance novel therapies. An interesting aspect of this story is how these collaborations may help Wave Life Sciences expand its research reach while sharing development and commercialization expertise with larger pharmaceutical companies. Next, we will examine how the PRISM RNA medicines platform...

The Molina Healthcare (MOH) share move was driven by a policy shock after the Centers for Medicare & Medicaid Services proposed just a 0.09% net payment increase for 2027 Medicare Advantage plans. See our latest analysis for Molina Healthcare. At a share price of US$179.59, Molina’s recent 1 day share price return of a 2.89% decline and 7 day share price return of an 11.05% decline sit against a 90 day share price return of 17.33%. The 1 year total shareholder return of a 42.14% decline...

EMCOR Group has recently attracted positive attention after highlighting strong financial strength, profitability, and growth metrics, supported by rising demand across key electrical and mechanical construction end markets and several 2025 acquisitions, including Miller Electric. The company’s raised 2025 revenue, operating margin, and EPS outlook, alongside high-quality analyst endorsement, underscores management’s confidence and its perceived competitive position within facilities...

Kering has recently confronted a steep revenue drop at Gucci and a restructuring plan at Alexander McQueen that could cut about one third of its workforce, reflecting weaker luxury demand and pressure in key markets such as China. Together, Gucci’s identity reset and Alexander McQueen’s cost-focused overhaul highlight how Kering is rethinking its brand portfolio amid a broader luxury slowdown. We’ll now examine how Gucci’s ongoing brand identity challenges shape Kering’s overall investment...

Immunocore Holdings (NasdaqGS:IMCR) announced an overhaul of its R&D leadership following the planned departure of EVP of Research & Development, Dr. David Berman. Instead of appointing a direct successor, the company is expanding the responsibilities of internal leaders Dr. Mohammed Dar and Mark Moyer. The leadership changes are expected to reshape how Immunocore manages clinical development and regulatory activities. Immunocore Holdings enters this leadership transition with its shares...

CorMedix (NasdaqGM:CRMD) is hosting an analyst day focused on its late stage clinical programs. The event will feature updates on REZZAYO for fungal infection prophylaxis and DefenCath for catheter related bloodstream infection prevention. Management is expected to outline current program status and broader business direction for these key assets. For investors watching CorMedix, the focus is on how these late stage assets fit into the broader infection prevention space. REZZAYO and...

Why Heineken (ENXTAM:HEIA) is on investors’ radar today Heineken (ENXTAM:HEIA) is back in focus after recent performance data highlighted mixed short term returns. The share price has been roughly flat over the past month but has shown gains over the past 3 months. For investors tracking longer horizons, the stock’s roughly 6% total return over the past year sits alongside weaker 3 year and 5 year total returns. This contrast may prompt closer attention to the current valuation and...

December sales update and why it matters for Rakus shareholders Rakus (TSE:3923) reported preliminary unaudited consolidated sales of ¥5,239 million for December 2025, equal to 124.2% year on year, a data point that naturally puts recent share price moves in context for investors. See our latest analysis for Rakus. The December sales update arrives after a weak stretch for the share price, with a 30 day share price return of 15.33% decline and a 1 year total shareholder return of 9.25%...

Madrigal Pharmaceuticals (MDGL) has recently drawn attention after a mixed pattern in its share performance, with a negative month return but a positive move over the past 3 months and a strong one year total return. See our latest analysis for Madrigal Pharmaceuticals. Recent trading has been choppy, with a 30 day share price return of a 16% decline and a year to date share price return of an 18% decline, yet the 1 year total shareholder return of 46% suggests longer term momentum has still...

If you are wondering whether Meituan at HK$97.20 is starting to look like value after a long slide, this piece walks through what the current market price might be implying about the business. The stock has seen a 0.4% decline over the last week, a 5.9% decline over the past month, and a 7.1% decline year to date, extending a 34.4% decline over 1 year and a 75.8% decline over 5 years. Recent coverage around Meituan has largely focused on how the company is positioned within China's consumer...

If you are wondering whether Travere Therapeutics at around US$31.09 is offering fair value or an opportunity, you are not alone. This article is built to help you size that up clearly. The stock has had a mixed run, with a 5.6% gain over the last 7 days but an 18.6% decline over 30 days, while still sitting on a 52.0% return over 1 year and 43.1% over 3 years, compared with a 2.1% decline over 5 years. Recent coverage of Travere Therapeutics has focused on its position in the...

Recent high grade silver gold drilling results and more than A$60 million in fresh funding at the Cerro Bayo project have pushed Andean Silver (ASX:ASL) firmly back onto investor watchlists. See our latest analysis for Andean Silver. The latest drilling results and funding news come against a volatile trading backdrop, with the A$2.15 share price sitting below recent highs after a 1 day share price return decline of 8.12% and a 7 day share price return decline of 17.62%. However, the 90 day...

Gränges FY 2025 earnings put recent momentum and margins under the microscope Gränges (OM:GRNG) has wrapped up FY 2025 with fourth quarter revenue of about SEK 7.2b and Basic EPS of SEK 2.31, while trailing twelve month figures sit at SEK 28.4b in revenue and SEK 9.55 in EPS. This gives investors a clear read on the latest run rate. The company has seen quarterly revenue move from SEK 6.18b and EPS of SEK 1.67 in Q4 2024 to SEK 7.22b and EPS of SEK 2.31 in Q4 2025. Over the same window,...

Duke Energy prepared for severe winter weather in the Carolinas and Florida with grid hardening work and customer safety outreach. The company activated response plans as storms moved through, leading to widespread outages across parts of its service territory. Crews were deployed for large scale restoration efforts, supported by advanced self healing grid technologies aimed at shortening outages. Duke Energy, trading as NYSE:DUK, sits at the center of a major power reliability story as...

PACE cost program shifts the focus for Wacker Chemie (XTRA:WCH) Wacker Chemie (XTRA:WCH) has launched its largest cost reduction program, PACE, after reporting 2025 results in line with expectations but under pressure from weak demand, lower capacity utilization and unfavorable currency effects. See our latest analysis for Wacker Chemie. The PACE announcement comes after a mixed run for investors, with the share price at €68.65, a 1-day share price return of 1.70% but a year to date share...

TeraWulf (WULF) is drawing fresh investor attention after securing large financing for high performance computing and AI facilities, backed by long term HPC contracts and support from partners such as Google and Fluidstack. See our latest analysis for TeraWulf. The latest funding news comes after a sharp pullback, with a 1 day share price return of an 8.05% decline and a 7 day share price return of a 5.31% decline. However, the 30 day share price return of 16.36% and the very large 3 year...

If you are wondering whether General Dynamics shares still offer value after a strong run, this article walks through what the current price might be implying about the business. The stock last closed at US$351.09, with a 1 year return of 39.3% and a 5 year return of 146.4%, while the past week shows a 3.4% decline and the past month a 4.3% gain. These figures can change how investors think about both opportunity and risk. Recent news coverage has focused on General Dynamics as a major US...

Multiple securities fraud class action lawsuits have been filed against F5, Inc. over an alleged failure to disclose a significant cybersecurity breach in its BIG-IP product. Regulatory investigations are reportedly examining whether F5 misrepresented the scope and impact of state-sponsored hacking and source code exfiltration. The actions focus on the potential gap between F5's prior public statements and the later disclosure of the BIG-IP security incident. F5, Inc. (NasdaqGS:FFIV)...

Abercrombie & Fitch (ANF) is back in focus after being named the NFL's Official Fashion Partner for the upcoming Super Bowl, tying its stock story to high visibility events across sports and fashion. See our latest analysis for Abercrombie & Fitch. The Super Bowl tie up comes at a time when Abercrombie & Fitch’s share price of $97.63 sits below recent highs. A 90 day share price return of 34.57% contrasts with a 22.44% decline over 30 days and a three year total shareholder return of 224.68%,...

Agnico Eagle Mines (NYSE:AEM) has agreed to sell its remaining 55% stake in Gunnarn Mining AB, including the Barsele project, to Goldsky Resources. The company will retain a royalty interest on the project, aligning with its portfolio optimization approach. The transaction structure includes cash, equity in Goldsky Resources, and ongoing royalty exposure. Agnico Eagle Mines is a major gold producer, so any portfolio reshaping around projects like Barsele can matter for how its asset base...

If you are wondering whether Southwest Airlines is still fairly priced after its recent run, you are not alone. This article focuses squarely on what the current share price might be implying. The stock recently closed at US$47.52, with returns of 13.3% over 7 days, 15.0% over 30 days, 15.1% year to date, 58.1% over 1 year and 39.8% over 3 years, while the 5 year return stands at 2.0%. Recent headlines around Southwest Airlines have focused on its operational recovery and route capacity...

West African Resources recently reported strong quarterly results from its Burkina Faso gold operations, with Kiaka outperforming Sanbrado for the first time and group operating cash flow approaching A$400 million, lifting cash and unsold bullion to more than A$750 million despite higher local taxes and royalties. At the same time, major investors including Mitsubishi UFJ Financial Group and Morgan Stanley ceased being substantial shareholders, reshaping the company’s institutional register...

If you are wondering whether NexGen Energy’s share price still offers value or has already run ahead of itself, you are not alone. The stock last closed at CA$17.10, with returns of 35.4% over the past 30 days, 21.4% year to date, and 80.2% over the last year, although the most recent 7 days showed a 0.9% decline. Recent moves in NexGen Energy have been framed by ongoing interest in uranium focused companies and attention on NexGen’s flagship Rook I project, which has kept the stock on many...

Dividend declaration and why it matters now Marathon Petroleum (MPC) has just declared a US$1.00 per share common stock dividend, payable on March 10, 2026 to shareholders of record at the close of business on February 18, 2026. See our latest analysis for Marathon Petroleum. At a share price of US$176.19, Marathon Petroleum has seen an 8.34% 1 month share price return and a 6.69% year to date share price return, while its 1 year total shareholder return of 23.60% and very large 5 year total...